Abstract
Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality. Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above 60%, more than 50% of patients are diagnosed at or beyond stage III when distant metastasis has already occurred, in which case 5 year survival rate drops to 10%. Chemotherapeutic intervention coupled with surgery is the backbone of metastatic CRC treatment and the only means of enhanced survival. For decades following its discovery, an antimetabolite 5- fluorouracil (5-FU) was the only chemotherapeutic agent available to successfully improve 12 month survival in CRC patients. Treatment of metastatic CRC has been considered palliative for many years; aiming to increase the duration and quality of the patient's remaining life, with little hope of cure, highlighting the need for novel DNA and RNA targeted therapies in the treatment of CRC. Over the last several decades, combinations of several chemotherapeutic agents have been incorporated into routine clinical practice. Combination regimes incorporating irinotecan, a semisynthetic inhibitor of topoisomerase, oxaliplatin, a third-generation platinum compound that causes mitotic arrest via the formation of DNA adducts, and capecitabine, a 5-FU prodrug, are now all established options for use as first-line, second-line and sequential treatment of CRC. This review provides a brief overview of the evolution of CRC chemotherapy as well as new and emerging treatment options.
Keywords: Colorectal cancer, chemotherapy, 5-fluorouracil, capecitabine and leucovorin, cisplatin and oxaliplatin, combination chemotherapy, targeted therapies and anti-inflammatories, ruthenium, PARP inhibitors.
Current Medicinal Chemistry
Title:Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches
Volume: 24 Issue: 15
Author(s): Rachel M. McQuade, Vanesa Stojanovska, Joel C. Bornstein and Kulmira Nurgali*
Affiliation:
- Centre for Chronic Diseases, College of Health and Biomedicine, Victoria University, Western Centre for Health, Research and Education, 176 Furlong Road, St. Albans, 3021, VIC,Australia
Keywords: Colorectal cancer, chemotherapy, 5-fluorouracil, capecitabine and leucovorin, cisplatin and oxaliplatin, combination chemotherapy, targeted therapies and anti-inflammatories, ruthenium, PARP inhibitors.
Abstract: Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality. Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above 60%, more than 50% of patients are diagnosed at or beyond stage III when distant metastasis has already occurred, in which case 5 year survival rate drops to 10%. Chemotherapeutic intervention coupled with surgery is the backbone of metastatic CRC treatment and the only means of enhanced survival. For decades following its discovery, an antimetabolite 5- fluorouracil (5-FU) was the only chemotherapeutic agent available to successfully improve 12 month survival in CRC patients. Treatment of metastatic CRC has been considered palliative for many years; aiming to increase the duration and quality of the patient's remaining life, with little hope of cure, highlighting the need for novel DNA and RNA targeted therapies in the treatment of CRC. Over the last several decades, combinations of several chemotherapeutic agents have been incorporated into routine clinical practice. Combination regimes incorporating irinotecan, a semisynthetic inhibitor of topoisomerase, oxaliplatin, a third-generation platinum compound that causes mitotic arrest via the formation of DNA adducts, and capecitabine, a 5-FU prodrug, are now all established options for use as first-line, second-line and sequential treatment of CRC. This review provides a brief overview of the evolution of CRC chemotherapy as well as new and emerging treatment options.
Export Options
About this article
Cite this article as:
McQuade M. Rachel, Stojanovska Vanesa, Bornstein C. Joel and Nurgali Kulmira*, Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches, Current Medicinal Chemistry 2017; 24 (15) . https://dx.doi.org/10.2174/0929867324666170111152436
DOI https://dx.doi.org/10.2174/0929867324666170111152436 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Validation and Development of N-glycan as Biomarker in Cancer Diagnosis
Current Pharmacogenomics and Personalized Medicine Circulating Tumor Cells in Cancer Therapy: Are we off Target?
Current Cancer Drug Targets Formulation Development and Characterization of Guar Gum Microspheres for Colon Delivery
Nanoscience & Nanotechnology-Asia Editorial [Hot Topic: Cancer Genetics (Guest Editor: Anirban Maitra)]
Current Molecular Medicine Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Possible Enhancement of Photodynamic Therapy (PDT) Colorectal Cancer Treatment when Combined with Cannabidiol
Anti-Cancer Agents in Medicinal Chemistry Synthesis, Anti-cancer Activity and Mechanism Study of 6-Mercapto-purine Derivatives
Letters in Drug Design & Discovery Antibodies and their Multivalent Constructs for Cancer Therapy
Protein & Peptide Letters Pharmacokinetics and In Vivo Fate of Drug Loaded Chitosan Nanoparticles<sup>++</sup>
Current Drug Metabolism Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic
Current Cancer Drug Targets Effect of Substituted Benzimidazoles and Somatostatin Analogs on the Vitality of Tumor Cell Lines and on the Oxidative Burst of Phagocytes
Letters in Drug Design & Discovery Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Bcl-2 Family Proteins Regulate Apoptosis and Epithelial to Mesenchymal Transition by Calcium Signals
Current Pharmaceutical Design Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Current Topics in Medicinal Chemistry The Role of Heat Shock Proteins in Cisplatin Resistance
Anti-Cancer Agents in Medicinal Chemistry Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Current Pharmaceutical Design Clinical Utility of Combined 18F-Fluoro-2-deoxyglucose Positron Emission Tomography – Computed Tomography in the Evaluation of Gastrointestinal Malignancies
Current Medical Imaging Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy Transcatheter Embolization Therapy in Liver Cancer
Recent Patents on Medical Imaging Bioinformatics Approaches for Anti-cancer Drug Discovery
Current Drug Targets